First Header Logo Second Header Logo

Connection

Haodong Xu to Diagnosis, Differential

This is a "connection" page, showing publications Haodong Xu has written about Diagnosis, Differential.
Connection Strength

0.859
  1. Fishbein GA, Grimes BS, Xian RR, Lee JM, Barjaktarevic I, Xu H. Primary salivary duct carcinoma of the lung, mucin-rich variant. Hum Pathol. 2016 Jan; 47(1):150-6.
    View in: PubMed
    Score: 0.113
  2. Ye J, Hameed O, Findeis-Hosey JJ, Fan L, Li F, McMahon LA, Yang Q, Wang HL, Xu H. Diagnostic utility of PAX8, TTF-1 and napsin A for discriminating metastatic carcinoma from primary adenocarcinoma of the lung. Biotech Histochem. 2012 Jan; 87(1):30-4.
    View in: PubMed
    Score: 0.085
  3. Mentrikoski MJ, Zhao C, Zhang J, Wang HL, McMahon LA, Yang Q, Li F, Xu H. Metastatic endometrial stromal sarcoma of the lung: importance of immunohistochemical staining, clinical history and imaging studies. Biotech Histochem. 2012 Jan; 87(1):35-9.
    View in: PubMed
    Score: 0.085
  4. Ye J, Findeis-Hosey JJ, Yang Q, McMahon LA, Yao JL, Li F, Xu H. Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Appl Immunohistochem Mol Morphol. 2011 Jul; 19(4):313-7.
    View in: PubMed
    Score: 0.084
  5. Findeis-Hosey JJ, Xu H. The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology. Hum Pathol. 2011 Mar; 42(3):303-14.
    View in: PubMed
    Score: 0.080
  6. Hu Y, Yang Q, McMahon LA, Wang HL, Xu H. Value of D2-40 in the differential diagnosis of pleural neoplasms with emphasis on its positivity in solitary fibrous tumor. Appl Immunohistochem Mol Morphol. 2010 Oct; 18(5):411-3.
    View in: PubMed
    Score: 0.080
  7. Mentrikoski MJ, Ma L, Pryor JG, McMahon LA, Yang Q, Spaulding BO, Scott GA, Wang HL, Xu H. Diagnostic utility of IMP3 in segregating metastatic melanoma from benign nevi in lymph nodes. Mod Pathol. 2009 Dec; 22(12):1582-7.
    View in: PubMed
    Score: 0.074
  8. Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H. IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol. 2008 Apr; 21(4):431-7.
    View in: PubMed
    Score: 0.066
  9. Wagner D, Joseph J, Huang J, Xu H. Malakoplakia of the prostate on needle core biopsy: a case report and review of the literature. Int J Surg Pathol. 2007 Jan; 15(1):86-9.
    View in: PubMed
    Score: 0.062
  10. Wu Y, Xu H, Zhu H, Zhu X, Liang J, Zeng Y, Zhang S, Yi X. [Clinical and histopathological features of colorectal sessile serrated adenoma/polyp and its differential diagnosis]. Zhonghua Bing Li Xue Za Zhi. 2014 Sep; 43(9):588-92.
    View in: PubMed
    Score: 0.026
  11. Desouki MM, Lioyd J, Xu H, Cao D, Barner R, Zhao C. CDX2 may be a useful marker to distinguish primary ovarian carcinoid from gastrointestinal metastatic carcinoids to the ovary. Hum Pathol. 2013 Nov; 44(11):2536-41.
    View in: PubMed
    Score: 0.025
  12. Klunder A, Subik K, Ye B, Xu H, Li F. Intimal sarcoma of the abdominal aorta presenting as a retroperitoneal mass. Pathology. 2012 Aug; 44(5):485-7.
    View in: PubMed
    Score: 0.023
  13. Levy M, Lin F, Xu H, Dhall D, Spaulding BO, Wang HL. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Hum Pathol. 2010 Sep; 41(9):1210-9.
    View in: PubMed
    Score: 0.019
  14. Yu L, Xu H, Wasco MJ, Bourne PA, Ma L. IMP-3 expression in melanocytic lesions. J Cutan Pathol. 2010 Mar; 37(3):316-22.
    View in: PubMed
    Score: 0.019
  15. Simon RA, di Sant'Agnese PA, Huang LS, Xu H, Yao JL, Yang Q, Liang S, Liu J, Yu R, Cheng L, Oh WK, Palapattu GS, Wei J, Huang J. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol. 2009 Feb; 40(2):252-8.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.